<DOC>
	<DOCNO>NCT00866138</DOCNO>
	<brief_summary>This phase 2 study design ass safety efficacy masitinib ( AB1010 ) patient relapsing/refractory ( 4 ; 14 ) Multiple Myeloma . Response progression assess accord Blad√© revise IMWG criteria1 low point .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Efficacy Safety Masitinib Patients With Relapse Refractory Multiple Myeloma With ( 4/14 ) Translocation Expressing Not FGFR3</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Confirmed multiple myeloma ( 4 ; 14 ) translocation FISH PCR , express express FGFR3 identify FACS Patients Multiple Myeloma progress relapse least two prior therapy ( include conventional chemotherapy and/or high dose therapy ) get reduction Mprotein le 75 % within 3 month high dose treatment ( Melphalan 200mg/m2 ) plateau obtain 3 month duration follow conventional chemotherapy Life expectancy &gt; 3 month Patient rapidly progressive disease cytopenia / renal failure stabilize chemotherapy ( possible 3 cycle VTD ( Bortezomib/Thalidomide/dexamethasone ) high dose Melphalan regimen follow 4 week washout period inclusion study . Patients must clearly detectable quantifiable monoclonal M component value ( &gt; 5 g/l ) serum / urine light chain excretion ( &gt; 0,5 g/d ) ECOG = 0 2 Prior corticosteroid within two week enrolment Prior local irradiation within two week enrolment Prior experimental standard treatment ( steroids local irradiation ) within 30 day enrolment Contraindication high dose steroid ( include ongoing active infection ) Patient treat cancer MM within 5 year enrolment , exception basal cell carcinoma cervical cancer situ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>( 4/14 )</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
</DOC>